USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Subscribe To Our Newsletter & Stay Updated